A growing list of editing tools can be used to make small changes to the genetic code, tweaking key nucleotides to address the underlying causes of diseases. But bigger edits are often needed, and ...
After becoming the first group to therapeutically edit human RNA in October 2024, Wave Life Sciences has released more data from its ongoing alpha-1 antitrypsin deficiency (AATD) clinical trial—and ...
RNA epigenetics also called Epitranscriptomics is an evolving field of research that explores chemical modifications on RNA and their impact on the cell and ...
From left to right: Ascidian Therapeutics' Chief Financial & Business Officer Dan Rosan, Senior Vice President and Head of Research Robert Bell, and Chief Medical Officer Jay Barth. Biotechnology ...
Wave Life Sciences (WVE) was not the only developer of RNA editing therapies to show significant stock gains from its historic proof-of-mechanism for its RNA editing platform, shown recently in the ...
A research team has uncovered new insights into the molecular mechanisms of ADAR1, a protein that regulates ribonucleic acid (RNA) induced immune responses. Their findings could open new pathways for ...
The most recent developments in the field of A-to-I RNA modification, with a special emphasis on the roles of A-to-I in the genesis and progression of cancer. Adenosine-to-inosine (A-to-I) RNA editing ...
Parkinson's disease (PD) is a neurodegenerative disorder in which the α-synuclein protein abnormally aggregates within brain cells, causing neuronal damage. Through international collaboration, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results